|
ERLEC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.92999982451659E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.16060000054929E-07 |
| Normal-vs-Stage2 |
2.161900E-04 |
| Normal-vs-Stage3 |
3.31501492922825E-12 |
| Normal-vs-Stage4 |
3.69589914228641E-11 |
| Stage1-vs-Stage2 |
9.526800E-01 |
| Stage1-vs-Stage3 |
5.864300E-03 |
| Stage1-vs-Stage4 |
1.219770E-03 |
| Stage2-vs-Stage3 |
1.123960E-01 |
| Stage2-vs-Stage4 |
2.411900E-02 |
| Stage3-vs-Stage4 |
2.375400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.5505043349815E-11 |
| Normal-vs-AfricanAmerican |
2.015400E-03 |
| Normal-vs-Asian |
1.98169999965359E-07 |
| Caucasian-vs-AfricanAmerican |
2.485600E-01 |
| Caucasian-vs-Asian |
7.933800E-01 |
| AfricanAmerican-vs-Asian |
3.889200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.62240040583129E-10 |
| Normal-vs-Female |
5.71920000247417E-09 |
| Male-vs-Female |
1.439970E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.1206999994684E-07 |
| Normal-vs-Age(41-60Yrs) |
2.47400000485953E-09 |
| Normal-vs-Age(61-80Yrs) |
2.96009994293911E-10 |
| Normal-vs-Age(81-100Yrs) |
6.997000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.130200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.958200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.989000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.663010E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.331800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.375000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.401800E-04 |
| Classical-VS-Follicular |
2.310400E-01 |
| Classical-VS-Other |
1.961960E-01 |
| Classical-VS-Normal |
1.12029996390817E-09 |
| Tall-VS-Follicular |
2.022400E-04 |
| Tall-VS-Other |
8.858000E-01 |
| Tall-VS-Normal |
5.61772850460329E-13 |
| Follicular-VS-Other |
1.734360E-01 |
| Follicular-VS-Normal |
1.233110E-04 |
| Other-VS-Normal |
1.959550E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.10809996920625E-09 |
| Normal-vs-N1 |
5.89350013235901E-10 |
| N0-vs-N1 |
1.268270E-02 |
|
|
